ADVERTISEMENT
Updated
blue and white sign for the entrance to the FDA that says U.S. Department of Health and Human Services Food and Drug Administration
Biogen’s Alzheimer’s Drug Gets FDA Approval, Mixed Reviews
A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.
Biogen’s Alzheimer’s Drug Gets FDA Approval, Mixed Reviews
Biogen’s Alzheimer’s Drug Gets FDA Approval, Mixed Reviews

A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.

A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.

neuroscience, neurodegeneration, drug development, disease & medicine

Eli Lilly Claims New Drug Can Slow Alzheimer’s-Related Decline
Lisa Winter | Mar 16, 2021 | 2 min read
Patients who received the drug fared better cognitively and functionally than those taking placebo, but still experienced losses in performance.
New Drug Combo for ALS Slows Decline in Small Clinical Study
Jef Akst | Sep 3, 2020 | 3 min read
After six months, patients with fast-progressing amyotrophic lateral sclerosis who had received the experimental treatment had less loss of function than those who received a placebo.
Interactive: Biomarkers in Blood Provide a Window into the Brain
Shawna Williams | Dec 1, 2019 | 1 min read
A look at some of the circulating molecules that may indicate various Alzheimer’s pathologies and serve as the bases of noninvasive tests for the disease.
The Hunt for a Blood Test for Alzheimer’s Disease
Shawna Williams | Dec 1, 2019 | 10 min read
Researchers hope circulating biomarkers will enable earlier detection and better monitoring of the neurodegenerative disorder—and perhaps help usher in new treatments.
ADVERTISEMENT